Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @BioXcel_Tx
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BioXcel_Tx
-
BioXcel Therapeutics Announces
@US_FDA Clearance of IND Application for#BXCL501 for the Treatment of#Opioid Withdrawal Symptoms.#agitationhttps://ir.bioxceltherapeutics.com/press-releases/detail/109/bioxcel-therapeutics-announces-fda-clearance-of-ind …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Through our use of
#AI and#ML,#BTAI is identifying the next wave of#medicines across#neuroscience & Immuno-#oncology. This is our commitment on#WorldCancerDay
and every day. This year's theme- #IAmAndIWill
pic.twitter.com/DxSg7s45OG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thanks,
@YahooFinance for the mention! "Get in On the#AI Health Care Revolution with@GlobusMedical@apple@amazon@Google"#BTAI#BXCL501#BXCL701https://finance.yahoo.com/news/ai-health-care-revolution-globus-231333236.html …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thank you
@AllieRN13 and@PharmaTechFocus for the in-depth article in@medicaltechmag- Triple Combo: Calming#Alzheimer's Agitation With#AI,#Wearables And A Novel Drug- highlighting@BioXcel_Tx and its phase 3 therapy.#BXCL501https://medical-technology.nridigital.com/medical_technology_jan20/triple_combo_calming_alzheimer_s_agitation_with_ai_wearables_and_a_novel_drug …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@BioXcel_Tx Announces 1st Patient Enrollment in Phase 1b/2 study of#BXCL501 for Acute Treatment of Agitation Associated with Dementia.https://ir.bioxceltherapeutics.com/press-releases/detail/108/bioxcel-therapeutics-announces-first-patient-enrolled-in …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@BioXcel_Tx Initiates Phase 3 Studies for Acute Agitation in Patients with#Schizophrenia and#Bipolar Disorder.https://www.bioxceltherapeutics.com/news-media/press-releases/detail/107/bioxcel-therapeutics-announces-initiation-of-pivotal-phase …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#BTAI Expands Study of#BXCL701 into Multiple Advanced Solid Tumor Types.#BXCL701 May Improve#Patient Response When Combined with#Checkpointinhibitors. Trial Expands Studies of#BXCL701 in#Prostate and#Pancreatic#Cancers.https://ir.bioxceltherapeutics.com/press-releases/detail/106/bioxcel-therapeutics-to-expand-study-of-bxcl701-into …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#BTAI Prepares to Initiate Pivotal Phase 3 with#BXCL501 Following Positive End-of-Phase 2 Meeting with@US_FDAhttps://ir.bioxceltherapeutics.com/press-releases/detail/105/bioxcel-therapeutics-prepares-to-initiate-pivotal-phase-3 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Happy Thanksgiving, from all of us at
@BioXcel_Tx!#biopharma#HappyThanksgivingpic.twitter.com/qUvxLNMEFp
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our CEO, Dr. Vimal Mehta, will present at the @PiperJaffrayCo 31st Annual Healthcare Conference in New York, Tuesday, Dec. 3, 2019, from 11:50 am to 12:10 pm ET. A live webcast will be accessible through the company's website http://www.bioxceltherapeutics.com .https://ir.bioxceltherapeutics.com/press-releases/detail/104/bioxcel-therapeutics-to-present-at-the-piper-jaffray-31st …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We're excited to see our
#AI#Innovation lab featured on@WTNH News 8! Thank you@jocelynmaminta and@mpiskorskimedia!#BTAI is using#AI to develop a new therapy for#acuteagitation. Check out the story here!https://www.wtnh.com/lifestyle/health-news/ct-company-meets-challenging-medical-needs-with-artificial-intelligence/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our CFO, Richard Steinhart, was thrilled to share his thoughts with Jack Sweeney
@CFOTL on#BTAI's use of#AI in drug development. Richard reveals why@BioXcel_Tx is a standout in a crowded space. Check out Richard's interview here!https://cfothoughtleader.com/cfopodcasts/546-richard-steinhart-cfo-bioxcel-therapeutics/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today, and every day, we honor all those who’ve answered the call to serve this great nation. Thank you for your bravery, service, and tremendous sacrifice from
#BTAI. Happy#VeteransDay!pic.twitter.com/UgvQ6ZpCDbHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#DYN#prostatecancer is the 2nd leading cause of#cancer death in men?#November is dedicated to raising awareness for#menshealth.#BTAI is teaming w/@Merck to evaluate#BXCL701 in combination w/#Keytruda to treat#neuroendocrine#prostatecancer#tNEPC.#NoShaveNovember.pic.twitter.com/cIDn9Uc3BQHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our CEO and founder Dr. Vimal Mehta shared
#BXCL501's exciting news with@proactive_NA.#BTAI is developing#wearable (such as@apple watch) to help combat#agitation.#applewatch#bif2019pic.twitter.com/KaNFMsMsVi
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioXcel Therapeutics proslijedio/la je Tweet
Dr. Vince O’Neill of
@BioXcel_Tx discusses safety and tolerability results from a phase 1b study testing BXCL701, a novel inhibitor of DPP8/9 / FAP, in combination with pembrolizumab in small cell/ neuroendocrine#ProstateCancer.#PCFRetreat19pic.twitter.com/22FVGIFIXm
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our sister company
@inveni_AI took a seat on@iambiotech's#BIF2019 panel discussing#AI in drug development. CEO and founder Krishnan Nandabalan's#AI &#ML platform is transforming#innovation.#awardwinning#inveniai#sanfranciscopic.twitter.com/suR40VYm9b
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our CMO, Dr. Vince O'Neill, presents safety & tolerability clinical results
#BXCL701@PCFnews Scientific Retreat.#BTAI study evaluates#BXCL701 in combo w/@merck#Keytruda for#neuroendocrine#prostatecancer#PCFTreat19https://ir.bioxceltherapeutics.com/press-releases/detail/101/bioxcel-therapeutics-to-present-at-the-26th-annual-prostate …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#BTAI highlights major milestones.#BXCL501 data expected 1H 2020.#BXCL701 data expected Q4 2019 & 1H 2020.https://ir.bioxceltherapeutics.com/press-releases/detail/100/bioxcel-therapeutics-highlights-upcoming-major-milestones …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#BTAI continues to follow and support#AlexTrebek in his courageous fight with stage 4#pancreaticcancer. We commend his grace and strength.#BXCL701 is a triple combination in development with@Pfizer@MerckGroup@NektarNews for#pancreaticcancer.https://www.cnn.com/2019/10/07/us/alex-trebek-pancreatic-cancer-hosting-trnd/index.html …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.